A man in his 60s suffered from refractory, biopsy-proven subacute cutaneous lupus
erythematosus that required chronic, moderate dose steroids to manage. His rash was
accompanied by arthralgias and negative autoantibody testing. His SCLE was responsive to tofacitinib but thrombotic complications limited the use of this medication.